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Myeloid/lymphoid or mixed-lineage leukemia (MLL)-family genes encode histone lysine 
methyltransferases that play important roles in epigenetic regulation of gene transcription, and 
these genes are frequently mutated in human cancers. While MLL1 and MLL4 have been the 
most extensively studied, MLL2 and its homolog MLL3 are not well-understood. Specifically, 
little is known regarding the extent of global MLL2 involvement in the regulation of gene 
expression and the mechanism underlying its alterations in mediating tumorigenesis. To study the 
role of MLL2 in tumorigenesis, we somatically knocked out MLL2 in a colorectal carcinoma cell 
line, HCT116. We observed that the MLL2 loss of function results in significant reduction of cell 
growth and multinuclear morphology. We further profiled MLL2 regulated genes and pathways 
by analyzing gene expression in MLL2 wild-type versus MLL2-null isogenic cell lines. Our 
results reveal the connection of MLL2 to multiple cellular signaling pathways and suggest 
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Modulation of chromatin accessibility through histone methylation is a critical step in 
regulating eukaryotic gene transcription. Histone H3 lysine 4 (H3K4) methylation by histone 
methyltransferases is an epigenetic mark for active gene transcription [1]. In human cells, four 
Mixed-Lineage Leukemia (MLL) family proteins have H3K4 methyltransferase activity, each 
with an enzymatic Su (var) 3–9 Enhancer-of-zeste Trithorax methyltransferase (SET) domain. 
These MLL-family genes include MLL1, MLL2 (also known as ALR/MLL4), MLL3, and MLL4 
(also known as MLL2 or Wbp7, conflicting with the official symbol for MLL2). Each of these 
proteins is associated with multiple subunits that function as a complex with histone-modifying 
activities [2]. Among the MLL genes, MLL1 and its homologue, MLL4, have been the most 
extensively studied. MLL1 is frequently involved in genetic alterations in acute myeloid and 
acute lymphoblastic leukemia [3]. Overexpression of MLL4 has been found in breast and 
colorectal cell lines and primary tissues [4].  
MLL2 was originally cloned as a human homolog of Drosophila trithorax [5]. MLL2 and 
its homolog, MLL3, function distinctly from MLL1 and MLL4. Both MLL2 and MLL3 associate 
with nuclear receptor coactivator 6 (NCOA6, also known as Activating Signaling Cointegrator-2, 
ASC-2) to form a complex that contains other essential subunits, including ASH2L, RbBP5, 
WDR5, DPY30, PTIP, PA1, and UTX, a histone H3K27 demethylase [6-8]. The MLL2 or MLL3 
(hereafter named MLL2/MLL3) complex has been found to play an essential role as a coactivator 
for transcriptional activation by nuclear hormone receptors [9]. Previous studies have shown that 
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MLL2/MLL3 complexes regulate Homeobox (Hox) gene transcription, and that they play critical 
roles in PPARγ-dependent adipogenesis [10-12].  
With the latest high-throughput next generation sequencing, new cancer driver genes 
previously unlinked to human cancers have been discovered. Among these genes, the 
MLL2/MLL3 pathway is the most frequently mutated driver in an ever-growing list of cancers. 
Initially, our medulloblastoma (MB) exome sequencing revealed frequent cancer driver 
inactivating mutations of histone lysine methyltransferase gene MLL2, and its paralogue gene 
MLL3. These were altered in 16% of cases (passenger gene probability <0.001), a prevalence 
which is comparable to classic MB cancer genes such as CTNNB1 (12%). Most somatic MLL2 
gene mutations identified in MBs lead to frame-shift. [13]. Subsequent comprehensive studies 
involving larger numbers of well-classified MB samples have significantly extended these genetic 
findings and further confirmed that dysregulation of the MLL2/MLL3 pathway, including 
mutations in a MLL2 and MLL3-associated demethylase, UTX, plays an important role in driving 
various groups of human MBs [14-16]. These results clearly established the aberrant 
MLL2/MLL3 pathway as a bona fide cancer-driving pathway. 
In addition to its role in MB development, recent studies found that the MLL2/MLL3 
pathway is frequently mutated in other cancers (summarized in Table 1), including 89% of 
follicular lymphoma and 20%-30% of diffusive large B-cell lymphoma [17, 18]. MLL3 is also 
mutated in colorectal cancer [19, 20]. Other cancers that have recently been found to be driven by 
the aberrant MLL2/MLL3 pathway, mainly through MLL2 or MLL3 mutations, include renal 
[21], prostate [22] , bladder [23], gastric [24], liver [25], pancreatic [26], and lung [27, 28]. UTX 
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was also found to be mutated in a variety of human cancers with various frequencies [29]. 
Furthermore, germ line MLL2 inactivation has recently been found to be the major cause of 
Kabuki syndrome [30], a rare pediatric congenital disorder characterized by intellectual 
disabilities. Collectively, these findings place the MLL2/MLL3 pathway among the most 
frequently mutated pathogenic pathways that drive human cancers. 
In contrast to the well-documented genetic evidence about MLL2/MLL3 mutations, 
much less is known regarding the mechanism underlying the tumor suppressor roles of the 
MLL2/MLL3 pathway. A recent study showed that shRNA-mediated knockdown of MLL2 
resulted in reduced cancer cell growth and altered adhesion in HeLa cells, although the 
underlying mechanism and its relevance to tumorigenesis were unknown [7]. To further elucidate 
the role of MLL2 in tumorigenesis, we utilized recombinant adeno-associated virus (rAAV) to 
somatically knockout MLL2 in the colorectal cancer cell line, HCT116.   Knockout of MLL2 in 
human cells affects the expression of a variety of genes. We note a set of genes that are retinoic 
acid-responsive and may be directly regulated by MLL2. Finally, integrative pathway analysis 
uncovered various signaling pathways that are regulated by the MLL2 complex. Our results 
reveal the global and pathway-specific roles of MLL2 and suggest that it participates in regulating 



























































2. Materials and Methods 
2.1 Cell Culture 
Human colorectal carcinoma cell line HCT116 (American Type Culture Collection) was 
cultured in McCoy’s 5A medium (Gibco) with 10% (vol/vol) FBS (HyClone). Cells were grown 
up to 70% confluency in 100 × 20 mm cell culture dishes (Corning) for genomic DNA, RNA, or 
nuclear protein extraction. HCT116-MLL2
−/−
 cells were maintained in complete medium 
containing 0.5 mg/mL Geneticin. HEK 293FT cells (Invitrogen) were cultured in DMEM with 
high glucose (Gibco) containing 10% (vol/vol) FBS and used for rAAV targeting virus 
production as previously described [32]. Exponentially growing cells were used for microarray 
gene expression profiling. For retinoic acid treatment, ~10
6
 cells in six-well plates were treated 
with 1 μM all-trans retinoic acid (Sigma) for 48 hours before cells were harvested for RNA 
preparation. 
2.2 Somatic Targeting 
The vector and protocol for epitope tag targeting and gene knockout have been described 
previously [33-35] . To generate MLL2-knockout cell lines, we utilized a rAAV vector to insert a 
stop codon right before the SET domain (amino acid 5391Leu), which is the enzymatic functional 
domain of MLL2. The rAAV vector was composed of two homology arms which were ∼1–1.2 
kb in length and surrounded the insertion site, and a neomycin (neo) selection marker surrounded 
by two loxP sites. The homology arms were amplified from HCT116 genomic DNA using 
Hotstart High-Fidelity Platinum Taq polymerase (Invitrogen). 
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Using Lipofectamine 2000 (Invitrogen), the vector was co-transfected with pAAV-RC 
and pHelper plasmids (Invitrogen) into HEK 293FT cells to generate rAAV targeting virus using 
a modified procedure based on the previously described protocol [33, 35]. Virus was harvested 2 
days after transfection. HCT116 cells were infected with targeting virus for 5 hours. Cells were 
allowed to recover in complete culture medium for 2 days, and were serially diluted into 96-well 
plates in culture media containing 0.5 mg/mL Geneticin. Geneticin-resistant cells were grown for 
14–21 days, harvested for Lyse-N-Go genomic DNA extraction (Thermo Scientific), and 
screened by PCR using two sets of primers (see Table 2 for primer information). The first set of 
primers has the forward primer, P1, located in the genome, upstream of the left homologous arm, 
and the reverse primer, NR, is located in the neo marker insertion region. The second set of 
primers has the forward primer, NF, located in the neo marker insertion region, and reverse 
primer, P2, located downstream of the right homologous arm in the genome. The screening PCR 
products that identified positive clones were confirmed by sequencing (Genewiz). 
Positive clones were then infected with Cre recombinase-expressing adenovirus (Vector 
Biolabs) to remove the drug-resistance selection marker. Cells were serially diluted and cultured 
in complete media for 10–14 days, and clones were picked for PCR screening using primers P3 
and P4 (see Table 2 for primer information). 
After the generation of MLL2
+/−
 cell lines, two independent MLL2
+/−
 lines were used for 
targeting the second MLL2 allele in exactly the same manner to generate MLL2
−/−
 cell lines. The 
neomycin selection marker in the second MLL2 allele was not removed. MLL2 knockout 
(MLL2
−/−
) was confirmed by genotyping, sequencing (Genewiz) the mutant transcript (RT-PCR), 
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and anti-MLL2 immunoblot. 
2.3 Nuclear Extraction 
Chemicals were ordered from Sigma unless otherwise stated. Briefly, ~1 x 10
7
cells were 
harvested, washed with buffer A (10 mM Hepes·KOH (EMD), pH 7.9, 1.5 mM magnesium 
chloride, 10 mM potassium chloride, 0.5 mM DTT, 5 mM sodium fluoride, 2 μM sodium 
orthovanadate (MP Biomedical), protease inhibitor cocktail (Roche)), and lysed in buffer A with 
0.1% Nonidet P-40. The nuclei were collected by centrifugation (4 °C, at 3500 g for 5 min) and 
lysed in high-salt buffer C (20 mM Hepes·KOH, pH 7.9, 1.5 mM magnesium chloride, 420 mM 
sodium chloride, 0.2 mM EDTA (Gibco), 25% (vol/vol) glycerol, 0.5 mM DTT, 5 mM sodium 
fluoride, 2 μM sodium orthovanadate, protease inhibitor mixture) at 4 °C on rotating mixer. 
Nuclear lysate was directly used for immunoblot.  
2.4 Western Blot 
Nuclear extract was resolved on 4–12% SDS/PAGE using NuPAGE system (Invitrogen). 
The blot was transferred on a piece of nitrocellulose paper using a TE22 tank transfer unit 
(Hoefer) filled with transfer buffer (1x NuPAGE transfer buffer, 0.1% SDS, 5% methanol, 
8.75mM 2-Mercaptoethanol) under 400mA or 100V at 4 °C for 4 hours. Nitrocellulose papers 
with the blots were then blocking with 1% casein in Tris-buffered saline (TBS, 50mM Tris-HCl, 
pH 7.5, 150mM NaCl) (Bio-rad) at 4 °C for overnight. The blots were stained with 1:1000 diluted 
anti-MLL2 antibody (gift from Dr. Kai Ge [6]) in blocking buffer at room temperature for at least 
2 hours, and wash with TBS with 0.05% Tween-20 (TBST) for 10 mins, 3 times. HRP-
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conjugated goat anti-rabbit or anti-mouse IgG (1mg/mL) were diluted 1:5000 in the blocking 
buffer, and incubate with the blots for 0.5 hours at room temperature, and wash with TBST for 10 
mins, 3 times. The blots were developed with SuperSignal West Femto Chemiluminescent 
Substrate (Pierce). The membrane was exposed to film for 0.5-10 mins. 
2.5 MTT Assay 
MTT assay was used to determine the cell viability and cell growth. About 10
4
 cells were 
plated in 96-well plate on day 0, and MTT assay was performed daily for 4 days to evaluate the 
overall proliferation of the cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide; Sigma) was dissolved in PBS at 5 mg/ml and filtered with 0.2 um filter for sterilization. 
On each day, 10ul of stock MTT solution were diluted in 100ul fresh culture medium, and added 
into the wells to be tested. The plates were incubated at 37°C for 4 hours.  After incubation, 200 
ul of acid-isopropanol (1 portion of 4N HCl : 100 portion of isopropanol) was added to all wells 
and mixed by pipetting thoroughly to dissolve the dark blue crystals. The plates were read on a 
POLARstar Optima microplate reader, using a test wavelength of 570 nm to determine the 
relative cell viability. Plates were normally read within 1 hours of adding the isopropanol. 
2.6 Microarray Assay 
Total RNA was prepared from MLL2
−/−
 cells (two pairs of cell lines, clone 1, 2 and cell 
line clone 3, 4, which were derived from two independent MLL2
+/−
 progenitor lines, were 
included for two separate microarray experiments) and HCT116 parental cells. The quality of the 
RNA was assessed with a 2100 Bioanalyzer G2939A (Agilent Technologies) and Nanodrop 8000 
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spectrophotometer (Thermo Scientific). Hybridization targets were prepared with a MessageAmp 
Premier RNA Amplification Kit (Applied Biosystems/Ambion) from total RNA, hybridized to 
GeneChip U133 Plus 2.0 arrays in Affymetrix GeneChip Hybridization Oven 645, washed in 
Affymetrix GeneChip Fluidics Station 450, and scanned with Affymetrix GeneChip Scanner 7G 
according to standard Affymetrix GeneChip hybridization, wash, and stain protocols. Each cell 
line was done in triplicate. Statistical analysis for false discovery rate was performed by 
significance analysis of microarrays [36]. Statistical analysis for the enrichment of down-
regulated genes in the ChIP-identified genes was performed by χ2 test. 
2.7 Confirmation of Microarray Gene Expression 
The expression change of selected genes was confirmed by RT-qPCR in the original 
microarray- analyzed pair of MLL2
−/−
 cell lines (clones 1 and 2) and in additional MLL2
−/−
 clones 
(clones 3 and 4) derived from two independent MLL2
+/−
 progenitor lines. Total RNA was 
prepared from parental cell lines and MLL2
−/−
 cells using a total RNA kit (Omega Bio-Tek) 
according to the manufacturer’s instructions. One microgram of total RNA was used for reverse 
transcription using a SuperScript II First-Strand Synthesis Kit (Life Technologies) according to 
the kit manual. After transcription, the cDNA was diluted 1:20 and used as template for qPCR.  
SYBR green-based real-time qPCR was performed with an Applied Biosystems 7900 
platform (Life Technologies). Quantitative PCR was done in 20-μL reactions containing 1× PCR 
buffer (67mMTris·HCT,pH8.8, 6.7mMMgCl2, 16.6 mM NH4SO4, 10 mM 2-mercaptoethanol), 2 
mM dNTPs, 0.5 μM forward and reverse primers, 6% (vol/vol) DMSO, 1:2,000 SYBR green, and 
1 unit Platinum Taq (Invitrogen). The PCR program was 95 °C, 10 min for hotstart, amplification 
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for 38 cycles (95 °C, 15 s to 60 °C, 15 s to 72 °C, 15 s), and a dissociation curve analysis (95 °C, 
15 s to 60 °C, 15 s to 95 °C, 15 s, ramp rate 2%).Gene expression levels were normalized to the 
housekeeper gene GAPDH (see Primers for list of primers used for qPCR). 
2.8 Microarray Data Analysis 
The web-based Ingenuity Pathway Analysis (IPA) (www.ingenuity.com) tool was used to 
analyze the genes down-regulated by >50% in the microarray. Top affected canonical pathways 
were identified for the down-regulated genes (Table 3).  
2.9 Chromatin Immunoprecipitation (ChIP) and ChIP-Quantitative PCR 
The ChIP procedure is described in detail in our previous publication. Briefly, cells were 
cross-linked and cell lysate was then prepared and subjected to sonication to shear the chromatin. 
Magnetic beads (New England BioLabs) conjugated with anti-Flag antibody (F3165; Sigma) 
were used for IP. ChIP-derived DNA was recovered for Illumina GAII-compatible library 
preparation. Libraries were used for sequencing or qPCR analysis. High-throughput sequencing 
was performed on the Illumina GAII system. Tags were mapped to the human genome (release 
hg18) by using the Illumina alignment software Eland. 
2.10 ChIP-Quantitative PCR 
Primers were designed according to the enriched locus coordinates, and SYBR green-based 
real-time qPCR was performed with an Applied Biosystems 7900 platform (Life Technologies). 
A LINE-1 amplicon was used for normalization (refer to Table 2 of primers used for ChIP-qPCR). 
 11 
 
ChIP DNA preparation was done as described above. ChIP DNA (2.5 μL) was used as qPCR 
template. Quantitative PCR was done in 20-μL reactions containing 1×PCRbuffer 
(67mMTris·HCT,pH8.8, 6.7mMMgCl2, 16.6 mM NH4SO4, 10 mM 2-mercaptoethanol), 2 mM 
dNTPs, 0.5 μM forward and reverse primers, 6% (vol/vol) DMSO, 1:2,000 SYBR green, and 1 
unit Platinum Taq (Invitrogen). The PCR program was 95 °C, 10 min for hotstart, amplification 
for 38 cycles (95 °C, 15 s to 60 °C, 15 s to 72 °C, 15 s), and a dissociation curve analysis (95 °C, 
15 s to 60 °C, 15 s to 95 °C, 15 s, ramp rate 2%).  
2.11 Retinoic Acid Treatment 
HCT116 parental cells or MLL2
−/−
 cells were treated with retinoic acid (1 μM) for 48 h. 
Afterward, RNA preparation, reverse transcription to generate cDNA, and real-time qPCR were 


























3.1 Generation of Isogenic MLL2-Knockout Colorectal Cancer Cells 
To investigate the function of MLL2 and identify downstream events that were regulated 
by MLL2, microarray analysis of gene expression in the isogenic MLL2 deficient cells was 
performed. Two technical barriers have complicated our task: (1) the massive size of MLL2 
(5537 amino acid; MW=~600kD) makes gene engineering challenging; and (2) the lack of high 
quality antibodies. In addition, si-RNA and sh-RNA did not show significant knockdown in our 
cell lines. To overcome these technical challenges, we have applied recombinant adeno-
associated virus (rAAV)-based somatic knockin technology [33, 35] to insert a stop codon into a 
coding exon of the MLL2 gene in HCT116 cell line. We chose the HCT116 carcinoma cell line 
for our study, as it is a near-diploid cell line with well-defined key cancerous pathways. 
Furthermore, this cell line has homozygous MLL3-inactivating mutations, thus preventing 
compensatory effects from obscuring functional analysis. Using rAAV based somatic knock-in 
technology, we generated MLL2-null HCT116 cell lines, and effectively engineered inactivated 
MLL2 mutations similar to those that are frequently found in cancers (Fig. 1). As expected, cell 
lines with insertions in both MLL2 alleles (MLL2
−/−
) had complete loss of the wild-type MLL2 
genes and transcript, and had no detectable MLL2 protein due to the nonsense mutation and/or 


































































































































































































































































































































































3.2 Cell Growth Reduced in MLL2-knockout Cells 
To determine the biological function of MLL2, we observed the morphology and growth 
in MLL2 deficient cells. MTT assay was used to determine the cell growth in our MLL2-null 
cells compared with the parental HCT116. Our results showed an overall slower growth of the 
MLL2
-/-
 HCT116 cell lines (Fig 3A), consistent with the previous result of MLL2 knockdown in 
HeLa cells [7]. Further, the MLL2
-/-
 cells frequently displayed a flattened morphology and a 
multinucleated phenotype (Fig 3B). These results indicated that MLL2 deficiency plays roles in 
cell cycle defect and/or cell senescence.  
3.3 Gene Expression Analysis of Parental and MLL2-knockout Cells. 
To identify downstream events that were regulated by MLL2, microarray analysis was 
used to analyze gene expression in the parental HCT116 cells and four MLL2
-/-
 clones. Overall, 
while a list of genes were identified to be downregulated by MLL2 loss of function 
(Supplementary Dataset 1), most of the down-regulation of gene expression was moderate, in 
agreement with the observation that deletion of a single MLL-family gene has only minimal 
effects on global H3K4 methylation [37, 38]. Interestingly, there were also genes that displayed 
higher expression levels in MLL2
-/-
 cells than in the parental cells (Fig 4), consistent with an 
indirect effect. Gene expression changes were further verified by qPCR of transcripts from the 
four MLL2
-/-
 clones.  
To identify MLL2 direct transcriptional target genes, we further identified the MLL2 
binding profile and gene expression profile. Our analysis revealed that a subset of genes 
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associated with MLL2-bound loci [31] displays reduced expression in MLL2
-/-
 cell lines 
(Supplementary Dataset 1), including S100 alpha (S100A) families (Fig 5A ad 5B). The 
decreased expression was accompanied by reduced H3K4 trimethylation (Fig 5C), consistent 
with the effect of MLL2 loss of function; while minor or no change in H3K27 trimethylation 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4 MLL2 Regulates Gene Expression of Multiple Signaling Pathways 
To further gain an integrative view of the functional consequence of MLL2 in the context 
of cellular signaling pathways, we selected the genes whose expression was >50% down-
regulated by MLL2 loss of function and subjected them to IPA canonical pathway analysis 
(Supplementary Dataset 1). Analysis of pathways that may be regulated by MLL2 revealed the 
potential effects of MLL2 on a broad range of cellular processes. Among those signaling 
pathways that were found to be significantly related were cAMP-mediated signaling and 
retinoic acid receptor (RXR) signaling (Table 3). Our data also revealed hepatic cholestasis 
pathway and B-cell development pathway, consistent with previous studies [11, 17, 18, 39] 
3.5 MLL2 Regulates the Expression of the Retinoic Acid-Responsive Gene ASB2. 
We next sought to validate the functional role of MLL2 in regulating the transcription of 
the genes we identified. The pathway analysis revealed that one of the interesting categories of 
genes was those that respond to nuclear hormones. Interestingly, one of the pathways 
overrepresented in both MLL2-bound and MLL2-responsive gene sets was retinoic acid 
signaling. One of the genes that were linked to the MLL2 binding loci was ASB2 [31], whose 
expression was previously found to be induced by retinoic acid in leukemia cells [40, 41]. This 
gene was expressed at a relatively low level in parental HCT116 cells, and quantitative analysis 
of the ASB2 transcript showed that its expression was further reduced in the MLL2
−/−
 cell lines 
(Fig. 6A). To verify the role of the MLL2 complex in mediating the retinoic acid response, we 
tested whether HCT116 cells responded to retinoic acid transcriptionally using ASB2 as a 
marker gene. Treatment of parental HCT116 cells with retinoic acid induced robust ASB2 
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expression (Fig. 6B). Furthermore, whereas retinoic acid treatment also led to an increased 
ASB2 transcript level over a very low basal level in the MLL2
−/−
 cells, the expression level of 
ASB2 was significantly lower than the level seen in the MLL2-intact parental cells upon 
retinoic acid treatment (Fig. 6B), indicating that MLL2 involvement accounted for the majority 
of increased ASB2 expression in response to retinoic acid. Collectively, these results validated 
the roles of MLL2 uncovered by gene expression studies, and suggest an extensive involvement 






























































































































































































































































































































































































































In this study, we generated MLL2 knockout cell lines for identification of genes whose 
expression was affected by MLL2 loss of function. The MLL2 deficient cells display slower 
growth and multinuclear morphology, which indicate the MLL2 function in cell cycle and/or cell 
senescence. A further examination such as cell cycle progression assay and senescence assay will 
be required to confirm our result. In addition to the biological finding, our gene expression 
analysis revealed a list of genes that are regulated by the MLL2 complex. Pathway analysis 
showed that the MLL2 complex plays roles in multiple signaling pathways and cellular processes, 
including cAMP signaling pathway, and retinoic acid signaling pathway. By comparing with our 
previous result of MLL2 binding loci [31], a subset of genes that were bound by MLL2 displays 
significant lower expression level in MLL2-null cells. Among those genes, we notice that MLL2 
was associated with and likely directly regulated by the S100A family of genes, which encode 
proteins containing EF-hand calcium-binding motifs that regulate intracellular calcium signaling 
and participate in a number of cellular processes [42]. In particular, S100A2 was identified as a 
putative tumor suppressor [43, 44], possibly through regulating the p53 pathway [45]. The 
regulation of the S100A gene cluster by the MLL2 complex reveals an additional gene cluster 
that is transcriptionally co-regulated by an MLL-family epigenetic regulator. 
Our findings provide evidence to expand previously established links between H3K4 
methyltransferases and other pathways, and suggest that the roles of MLL2 may be extensive. 
Nuclear hormone receptors are among those at the top of the list in the transcription factor and 
pathway analysis from our gene expression profiling and binding sites of MLL2. In addition, 
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among the most interesting discoveries are the signaling pathways that were not previously 
known to be associated with MLL2 or MLL3 complexes, such as cAMP signaling. These findings, 
and those from previous work, provide insight that may inform the future search for mechanisms 
underlying the role of MLL2 in pathogenesis: (i) It is possible that one or more of these currently 
described pathways contributes to MLL2 mutation-mediated tumorigenesis in a cell type specific 
manner; (ii) comparing gene expression profiles (MLL2 wild-type versus mutant) in different 
cellular contexts may suggest the primacy of these pathways in tumors bearing MLL2 pathway 
alterations; and (iii) gene expression signatures characteristic of MLL2 mutations may be 
exploited for tumor classification. 
In summary, the present study advances our understanding of MLL2 in the following 
ways: (i) it identified various downstream pathways that are regulated by MLL2, establishing a 
basis for studying the mechanism underlying the role of MLL2 in development and disease; (ii) it 
uncovered the regulatory role of MLL2 in the transcription of clustered S100A-family genes that 
encode for a group of broadly distributed yet understudied proteins; (iii) it further established the 
extensive role of MLL2 in nuclear hormone signaling and provided a rationale for future studies 
on the link between nuclear hormone signaling and diseases associated with MLL2 alterations; 
and finally, (iv) our work further validated the somatic recombination-based approach for 
studying massive proteins, such as MLL2, for which overexpression is a challenging task. The 
findings and approaches undertaken here have laid the foundation for further understanding the 
function of MLL2 and have implications for future research on the rapidly accumulating list of 
epigenetic regulator genes that have been found to be altered in cancers and other diseases. 
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Supplementary Dataset 1 
Microarray gene expression profiling analysis. List of genes that were down-regulated (<70% of 
parental cells) or up-regulated (>160% of parental cells) in MLL2
-/-
 clone #1 and #2 and 
displayed significant change in #3 and #4.  
Affymetrix 












(average of  
















(average of  













g Table 3 
datad 
213110_s_at 
collagen, type IV, 
alpha 5 
COL4A5 -5.62 0.02 <0.0001 <0.0001 -4.54 0.04 <0.0001 <0.0001 No Yes 
201667_at 
gap junction 
protein, alpha 1, 
43kDa 
GJA1 -4.74 0.04 <0.0001 <0.0001 -3.88 0.07 <0.0001 <0.0001 No Yes 
226415_at 
vesicle amine 
transport protein 1 
homolog (T. 
californica)-like 
VAT1L -4.53 0.04 <0.0001 <0.0001 -3.14 0.11 <0.0001 <0.0001 No Yes 










CYP24A1 -3.69 0.08 <0.0001 <0.0001 -2.4 0.19 <0.0001 <0.0001 No Yes 
203186_s_at 
S100 calcium 
binding protein A4 
S100A4 -3.67 0.08 <0.0001 <0.0001 -3 0.13 <0.0001 <0.0001 No Yes 
206785_s_at 
killer cell lectin-like 
receptor subfamily 
C, member 1 /// 
killer cell lectin-like 
receptor subfamily 
C, member 2 
KLRC1 /// 
KLRC2 
-3.33 0.1 <0.0001 <0.0001 -2.23 0.21 <0.0001 <0.0001 No Yes 










SPARC -3.13 0.11 <0.0001 <0.0001 -2.54 0.17 <0.0001 <0.0001 No Yes 
207723_s_at 
killer cell lectin-like 
receptor subfamily 
C, member 3 

























LRP12 -2.72 0.15 <0.0001 <0.0001 -2.89 0.13 <0.0001 <0.0001 No Yes 
223435_s_at 
protocadherin 
alpha 1 /// 
protocadherin 
alpha 10 /// 
protocadherin 
alpha 11 /// 
protocadherin 
alpha 12 /// 
protocadherin 
alpha 13 /// 
protocadherin 
alpha 2 /// 
protocadherin 
alpha 3 /// 
protocadherin 
alpha 4 /// 
protocadherin 
alpha 5 /// 
protocadherin 
alpha 6 /// 
protocadherin 
alpha 7 /// 
protocadherin 
alpha 8 /// 
protocadherin 
alpha 9 /// 
protocadherin 
alpha subfamily C, 
1 /// protocadherin 
alpha subfamily C, 
2 
  -2.62 0.16 <0.0001 <0.0001 -1.98 0.25 <0.0001 <0.0001 No Yes 
240228_at 
CUB and Sushi 
multiple domains 3 






PKIA -2.5 0.18 <0.0001 <0.0001 -1.73 0.3 <0.0001 <0.0001 No Yes 
205229_s_at 
coagulation factor 
C homolog, cochlin 
(Limulus 
polyphemus) 





SOX9 -2.48 0.18 <0.0001 <0.0001 -1.64 0.32 <0.0001 <0.0001 No Yes 
213992_at 
collagen, type IV, 
alpha 6 












GDF15 -2.28 0.21 <0.0001 <0.0001 -0.96 0.51 <0.0001 <0.0001 No Yes 
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inhibitor (GDI) beta 




IL7R -2.09 0.23 <0.0001 <0.0001 -1.74 0.3 <0.0001 <0.0001 No Yes 
219710_at 
SH3 domain and 
tetratricopeptide 
repeats 2 
SH3TC2 -1.93 0.26 <0.0001 <0.0001 -1.42 0.37 <0.0001 <0.0001 Yes Yes 
219836_at 
zinc finger, BED-
type containing 2 





SOX4 -1.81 0.29 <0.0001 <0.0001 -1.67 0.31 <0.0001 <0.0001 No Yes 
210445_at 
fatty acid binding 
protein 6, ileal 
FABP6 -1.8 0.29 <0.0001 <0.0001 -2.38 0.19 <0.0001 <0.0001 No Yes 
205364_at 
acyl-CoA oxidase 
2, branched chain 
ACOX2 -1.77 0.29 <0.0001 <0.0001 -0.52 0.7 <0.0001 0.0011 No Yes 






TNFSF4 -1.76 0.3 <0.0001 <0.0001 -1.32 0.4 <0.0001 <0.0001 No Yes 
204971_at 
cystatin A (stefin 
A) 





IGFBP7 -1.7 0.31 <0.0001 <0.0001 -1.01 0.5 <0.0001 <0.0001 No Yes 




and ring finger 2 





SOX4 -1.65 0.32 <0.0001 <0.0001 -1.17 0.44 <0.0001 <0.0001 No Yes 
207534_at 
melanoma antigen 
family B, 1 






PKIB -1.6 0.33 <0.0001 <0.0001 -2.43 0.19 <0.0001 <0.0001 No Yes 
206104_at 
ISL LIM homeobox 
1 
ISL1 -1.58 0.33 <0.0001 <0.0001 -1.11 0.46 <0.0001 <0.0001 No Yes 
204268_at 
S100 calcium 
binding protein A2 
S100A2 -1.57 0.34 <0.0001 <0.0001 -1.11 0.46 <0.0001 <0.0001 Yes Yes 
1552334_at 
TRIO and F-actin 
binding protein 
TRIOBP -1.57 0.34 <0.0001 <0.0001 -0.97 0.51 <0.0001 <0.0001 No Yes 
203379_at 
ribosomal protein 
S6 kinase, 90kDa, 
polypeptide 1 




binding protein, R 
binder family) 





inhibitor (GDI) beta 
ARHGDIB -1.51 0.35 <0.0001 <0.0001 -1.92 0.26 <0.0001 <0.0001 No Yes 
203964_at 
N-myc (and STAT) 
interactor 












SOX4 -1.51 0.35 <0.0001 <0.0001 -1.12 0.46 <0.0001 <0.0001 No Yes 
231325_at 
unc-5 homolog D 
(C. elegans) 
UNC5D -1.49 0.36 <0.0001 <0.0001 -0.87 0.55 <0.0001 <0.0001 No Yes 




GPR56 -1.48 0.36 <0.0001 <0.0001 -0.91 0.53 <0.0001 <0.0001 No Yes 




DCLK1 -1.42 0.37 <0.0001 <0.0001 0.98 1.98 <0.0001 <0.0001 No Yes 
1552332_at 
TRIO and F-actin 
binding protein 











C homolog, cochlin 
(Limulus 
polyphemus) 
COCH -1.4 0.38 <0.0001 <0.0001 -1.04 0.49 <0.0001 <0.0001 No Yes 




family) member 2 
DHRS2 -1.35 0.39 <0.0001 <0.0001 -1.54 0.34 <0.0001 <0.0001 No Yes 
225968_at 
prickle homolog 2 
(Drosophila) 




TUBAL3 -1.34 0.4 <0.0001 <0.0001 -0.97 0.51 <0.0001 <0.0001 No Yes 
209443_at 
serpin peptidase 





SERPINA5 -1.33 0.4 <0.0001 <0.0001 -0.59 0.67 <0.0001 <0.0001 No Yes 














GPR110 -1.27 0.41 <0.0001 <0.0001 -1.3 0.41 <0.0001 <0.0001 No Yes 
204855_at 
serpin peptidase 
inhibitor, clade B 
(ovalbumin), 
member 5 
SERPINB5 -1.27 0.41 <0.0001 <0.0001 -1.28 0.41 <0.0001 <0.0001 No Yes 


















































PPP3CA -1.18 0.44 <0.0001 <0.0001 -0.87 0.55 <0.0001 <0.0001 Yes Yes 
201798_s_at myoferlin MYOF -1.18 0.44 <0.0001 <0.0001 -0.74 0.6 <0.0001 <0.0001 Yes Yes 



















FRMD5 -1.12 0.46 <0.0001 <0.0001 -0.95 0.52 <0.0001 <0.0001 No Yes 
203108_at 
G protein-coupled 
receptor, family C, 
group 5, member 
A 
GPRC5A -1.12 0.46 <0.0001 <0.0001 -0.75 0.59 <0.0001 <0.0001 No Yes 
204194_at 
BTB and CNC 













alpha 1 /// 
protocadherin 
alpha 10 /// 
protocadherin 
alpha 11 /// 
protocadherin 
alpha 12 /// 
protocadherin 
alpha 13 /// 
protocadherin 
alpha 2 /// 
protocadherin 
alpha 3 /// 
protocadherin 
alpha 4 /// 
protocadherin 
alpha 5 /// 
protocadherin 
alpha 6 /// 
protocadherin 
alpha 7 /// 
protocadherin 
alpha 8 /// 
protocadherin 
alpha 9 /// 
protocadherin 
alpha subfamily C, 
1 /// protocadherin 
alpha subfamily C, 
2 
#VALUE! -1.1 0.47 <0.0001 <0.0001 -0.65 0.64 <0.0001 <0.0001 No Yes 
223590_at 
zinc finger protein 
700 
ZNF700 -1.1 0.47 <0.0001 <0.0001 -1.15 0.45 <0.0001 <0.0001 No Yes 





ATAD2 -1.09 0.47 <0.0001 <0.0001 -1.27 0.42 <0.0001 <0.0001 Yes Yes 












ABCC3 -1.08 0.47 <0.0001 <0.0001 -1.27 0.41 <0.0001 <0.0001 Yes Yes 
209369_at annexin A3 ANXA3 -1.06 0.48 <0.0001 <0.0001 -0.39 0.76 0.0006 <0.0001 No Yes 




family) member 2 









GPR110 -1.05 0.48 <0.0001 <0.0001 -1.24 0.42 <0.0001 <0.0001 No Yes 
242127_at --- --- -1.04 0.49 <0.0001 <0.0001 -0.88 0.54 <0.0001 <0.0001 No Yes 
226776_at 
enhancer of yellow 
2 homolog 
(Drosophila) 
ENY2 -1.03 0.49 <0.0001 <0.0001 -0.63 0.65 <0.0001 0.0011 No Yes 
210276_s_at 
nucleolar protein 











protein 1 (9-27) 
IFITM1 -1.03 0.49 <0.0001 <0.0001 -0.84 0.56 <0.0001 <0.0001 No Yes 




















C14orf169 -0.98 0.51 0.0006 <0.0001 -0.53 0.69 <0.0001 <0.0001 No No 
216210_x_at 
TRIO and F-actin 
binding protein 
















C8orf47 -0.95 0.52 <0.0001 <0.0001 -1.41 0.38 <0.0001 <0.0001 No No 
218718_at 
platelet derived 
growth factor C 




KRTAP4-12 -0.95 0.52 0.0006 0.0017 -0.78 0.58 <0.0001 <0.0001 No No 
229606_at --- --- -0.94 0.52 <0.0001 <0.0001 -0.89 0.54 <0.0001 <0.0001 No No 
204011_at 
sprouty homolog 2 
(Drosophila) 












































DNAJC12 -0.89 0.54 <0.0001 <0.0001 -0.84 0.56 <0.0001 <0.0001 No No 
39248_at 
aquaporin 3 (Gill 
blood group) 











DECR1 -0.89 0.54 <0.0001 <0.0001 -0.65 0.64 <0.0001 <0.0001 No No 
204823_at neuron navigator 3 NAV3 -0.89 0.54 <0.0001 <0.0001 -1.94 0.26 <0.0001 <0.0001 No No 
231872_at 




LRRCC1 -0.89 0.54 <0.0001 <0.0001 -0.69 0.62 <0.0001 <0.0001 No No 
236105_at 
zinc finger and 
BTB domain 
containing 10 




PEG10 -0.87 0.55 <0.0001 <0.0001 -0.88 0.54 <0.0001 <0.0001 No No 




BMP regulator 1 
(chordin-like) 















BBS10 -0.86 0.55 <0.0001 <0.0001 -0.81 0.57 <0.0001 <0.0001 No No 
240239_at 
zinc finger protein 
566 


















SH3KBP1 -0.84 0.56 <0.0001 <0.0001 -0.77 0.59 <0.0001 <0.0001 No No 
202795_x_at 
TRIO and F-actin 
binding protein 



















DHTKD1 -0.82 0.57 0.0006 <0.0001 -0.8 0.58 <0.0001 <0.0001 No No 
217109_at 
mucin 4, cell 
surface associated 




integrin, alpha 3 
(antigen CD49C, 
alpha 3 subunit of 
VLA-3 receptor) 
ITGA3 -0.82 0.57 <0.0001 <0.0001 -1 0.5 <0.0001 <0.0001 Yes No 
211603_s_at ets variant 4 ETV4 -0.82 0.57 <0.0001 <0.0001 -0.48 0.72 <0.0001 <0.0001 No No 





PPIG -0.81 0.57 <0.0001 <0.0001 -0.67 0.63 <0.0001 <0.0001 No No 
228562_at 
zinc finger and 
BTB domain 
containing 10 












ABCC3 -0.8 0.57 0.0006 <0.0001 -0.83 0.56 <0.0001 <0.0001 Yes No 







UBE2H -0.8 0.58 <0.0001 <0.0001 -0.58 0.67 <0.0001 <0.0001 Yes No 














TM9SF2 -0.79 0.58 <0.0001 <0.0001 -0.69 0.62 <0.0001 <0.0001 No No 




TMEM133 -0.79 0.58 <0.0001 <0.0001 -0.88 0.54 <0.0001 <0.0001 No No 











LRP12 -0.78 0.58 0.0006 0.0017 -0.81 0.57 <0.0001 <0.0001 No No 
207763_at 
S100 calcium 
binding protein A5 
S100A5 -0.78 0.58 <0.0001 <0.0001 -0.77 0.59 <0.0001 <0.0001 No No 
232151_at 
metastasis 
associated in colon 
cancer 1 









zeta 2 (zygin II) 
FEZ2 -0.78 0.58 <0.0001 <0.0001 -0.57 0.67 <0.0001 <0.0001 No No 
231784_s_at 
DDB1 and CUL4 
associated factor 
13 




EGF -0.77 0.59 0.0006 <0.0001 -0.51 0.7 <0.0001 0.0011 No No 












TMEM64 -0.75 0.59 <0.0001 <0.0001 -0.32 0.8 0.0031 0.0011 No No 








family member V 
PAQR5 -0.75 0.6 <0.0001 <0.0001 -0.7 0.62 <0.0001 <0.0001 No No 




























elongation of long 





















elongation of long 




ELOVL6 -0.71 0.61 <0.0001 <0.0001 -0.37 0.78 <0.0001 <0.0001 No No 
222719_s_at 
platelet derived 
growth factor C 
PDGFC -0.71 0.61 <0.0001 <0.0001 -1.1 0.46 <0.0001 <0.0001 No No 
219123_at 
zinc finger protein 
232 




















N, member 4 
KCNN4 -0.7 0.61 <0.0001 <0.0001 -1.03 0.49 <0.0001 <0.0001 Yes No 
201691_s_at tumor protein D52 TPD52 -0.7 0.62 0.0006 <0.0001 -0.43 0.74 <0.0001 0.0011 No No 
219312_s_at 
zinc finger and 
BTB domain 
containing 10 
ZBTB10 -0.7 0.62 <0.0001 0.0017 -0.85 0.55 <0.0001 <0.0001 No No 
203998_s_at synaptotagmin I SYT1 -0.7 0.62 0.0006 <0.0001 -1.29 0.41 <0.0001 <0.0001 No No 




ECM1 -0.7 0.62 <0.0001 <0.0001 -0.38 0.77 <0.0001 <0.0001 No No 
239288_at 
TRAF2 and NCK 
interacting kinase 





SFTA1P -0.69 0.62 <0.0001 <0.0001 -2.55 0.17 <0.0001 <0.0001 No No 
213107_at 
TRAF2 and NCK 
interacting kinase 
TNIK -0.68 0.62 <0.0001 <0.0001 -1.18 0.44 <0.0001 <0.0001 No No 
211828_s_at 
TRAF2 and NCK 
interacting kinase 










STK3 -0.68 0.63 <0.0001 <0.0001 -0.27 0.83 0.016 0.0091 No No 
211538_s_at 
heat shock 70kDa 
protein 2 











PPIG -0.67 0.63 0.0006 <0.0001 -0.59 0.67 <0.0001 <0.0001 No No 




TMEM67 -0.67 0.63 <0.0001 <0.0001 -0.52 0.7 <0.0001 <0.0001 No No 




BMP regulator 1 
(chordin-like) 




HRSP12 -0.66 0.63 <0.0001 <0.0001 -0.59 0.66 <0.0001 <0.0001 No No 
209481_at SNF related kinase SNRK -0.65 0.64 <0.0001 <0.0001 -0.71 0.61 <0.0001 <0.0001 No No 
226124_at 
zinc finger protein 
90 homolog 
(mouse) 
ZFP90 -0.65 0.64 0.0006 <0.0001 -0.94 0.52 <0.0001 <0.0001 No No 








EGR4 -0.65 0.64 0.0009 0.0005 -1 0.5 <0.0001 <0.0001 No No 
1560587_s_a
t 














TERF1 -0.65 0.64 <0.0001 <0.0001 -0.37 0.78 0.0031 0.0039 No No 
213109_at 
TRAF2 and NCK 
interacting kinase 
TNIK -0.65 0.64 <0.0001 <0.0001 -1.35 0.39 <0.0001 <0.0001 No No 
205730_s_at 
actin binding LIM 
protein family, 
member 3 




substrate 2 (rho 
family, small GTP 
binding protein 
Rac2) 
RAC2 -0.64 0.64 <0.0001 <0.0001 -0.58 0.67 <0.0001 <0.0001 No No 
212364_at myosin IB MYO1B -0.64 0.64 0.0006 <0.0001 -0.5 0.71 <0.0001 0.0011 No No 
206027_at 
S100 calcium 
binding protein A3 
S100A3 -0.64 0.64 0.0016 0.0017 -0.86 0.55 <0.0001 <0.0001 No No 


















V1 subunit C1 















catalytic subunit 1 
PDP1 -0.63 0.65 <0.0001 <0.0001 -0.49 0.71 <0.0001 <0.0001 No No 






G2E3 -0.62 0.65 <0.0001 <0.0001 -0.55 0.68 <0.0001 <0.0001 No No 























ANKRD46 -0.6 0.66 <0.0001 <0.0001 -0.27 0.83 0.0006 0.0021 No No 
227307_at tetraspanin 18 TSPAN18 -0.6 0.66 <0.0001 0.0005 -0.38 0.77 <0.0001 0.0011 Yes No 










elongation of long 




ELOVL6 -0.6 0.66 <0.0001 <0.0001 -0.63 0.65 <0.0001 <0.0001 No No 
233899_x_at 
zinc finger and 
BTB domain 
containing 10 


































CAMK4 -0.59 0.66 <0.0001 <0.0001 -0.42 0.75 0.0006 0.0021 No No 
209505_at 
nuclear receptor 
subfamily 2, group 
F, member 1 
NR2F1 -0.59 0.67 <0.0001 0.053 -0.76 0.59 <0.0001 <0.0001 No No 
217914_at 
two pore segment 
channel 1 




initiation factor 3, 
subunit E 
EIF3E -0.58 0.67 <0.0001 <0.0001 -0.5 0.71 <0.0001 <0.0001 No No 
222496_s_at 
RNA binding motif 
protein 47 




protein), beta 1, 
88kDa 





















SULT1A1 -0.57 0.67 <0.0001 <0.0001 -0.42 0.75 <0.0001 <0.0001 No No 










MALT1 -0.57 0.67 <0.0001 0.0005 -0.77 0.59 <0.0001 <0.0001 No No 
227802_at 
RUN and FYVE 
domain containing 
3 





PPIG -0.57 0.67 0.0006 <0.0001 -0.69 0.62 <0.0001 <0.0001 No No 











ROCK1 -0.56 0.68 <0.0001 <0.0001 -0.56 0.68 <0.0001 <0.0001 No No 
219038_at 
MORC family CW-
type zinc finger 4 
MORC4 -0.56 0.68 <0.0001 <0.0001 -0.59 0.67 <0.0001 <0.0001 No No 
221020_s_at 
solute carrier 
family 25, member 
32 






















SH3KBP1 -0.56 0.68 <0.0001 0.0005 -0.55 0.68 <0.0001 <0.0001 No No 
218035_s_at 
RNA binding motif 
protein 47 






-0.55 0.68 0.0049 <0.0001 -0.61 0.66 <0.0001 <0.0001 No No 
231697_s_at --- --- -0.55 0.68 0.0049 <0.0001 -0.67 0.63 <0.0001 <0.0001 No No 
203584_at 
tetratricopeptide 
repeat domain 35 





ARHGAP42 -0.55 0.68 0.0009 <0.0001 -0.89 0.54 <0.0001 <0.0001 No No 
235696_at --- --- -0.55 0.68 <0.0001 <0.0001 -0.52 0.7 <0.0001 <0.0001 No No 
208763_s_at 
TSC22 domain 
family, member 3 


























164, member A 










DICER1 -0.54 0.69 0.0016 0.0005 -0.51 0.7 <0.0001 <0.0001 No No 
228489_at 
transmembrane 4 
L six family 
member 18 






EBAG9 -0.53 0.69 <0.0001 <0.0001 -0.59 0.67 <0.0001 <0.0001 No No 














-0.53 0.69 <0.0001 <0.0001 -0.38 0.77 0.0006 0.0021 No No 


















catalytic subunit 1 










82, member B 
FAM82B -0.52 0.7 0.0006 <0.0001 -0.72 0.61 <0.0001 <0.0001 No No 























EBAG9 -0.52 0.7 <0.0001 <0.0001 -0.6 0.66 <0.0001 <0.0001 No No 
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SPOCK3 0.69 1.62 0.0016 0.0017 0.47 1.39 0.0006 <0.0001 No No 















ERRFI1 0.7 1.63 <0.0001 <0.0001 0.58 1.5 <0.0001 <0.0001 No No 
1557302_at 
zinc finger protein 
585B 




TMOD2 0.7 1.63 0.0049 <0.0001 0.62 1.53 0.0031 0.0021 No No 






















EXOC1 0.76 1.69 <0.0001 <0.0001 0.75 1.68 <0.0001 <0.0001 No No 




ANKRD10 0.82 1.76 <0.0001 <0.0001 1.01 2.01 <0.0001 <0.0001 No No 




IVA, member 1 
PTP4A1 0.84 1.79 <0.0001 <0.0001 0.58 1.49 <0.0001 <0.0001 No No 
202388_at 
regulator of G-
protein signaling 2, 
24kDa 





RAB31 0.87 1.83 <0.0001 <0.0001 0.29 1.22 0.0069 0.0011 No No 
1559360_at --- --- 0.88 1.84 0.0004 <0.0001 0.68 1.6 <0.0001 <0.0001 No No 
205352_at 
serpin peptidase 
inhibitor, clade I 
(neuroserpin), 
member 1 
SERPINI1 0.88 1.84 <0.0001 <0.0001 0.66 1.58 <0.0001 <0.0001 No No 
206059_at 
zinc finger protein 
91 
ZNF91 0.88 1.85 <0.0001 <0.0001 0.95 1.93 <0.0001 <0.0001 No No 
212412_at 
PDZ and LIM 
domain 5 












DUSP4 0.89 1.86 <0.0001 <0.0001 0.72 1.65 <0.0001 <0.0001 No No 
227230_s_at KIAA1211 KIAA1211 0.9 1.86 <0.0001 <0.0001 0.47 1.39 <0.0001 <0.0001 No No 
211745_x_at 
hemoglobin, alpha 




0.9 1.87 <0.0001 <0.0001 0.64 1.56 <0.0001 <0.0001 No No 




111, member A 




KRTAP3-1 0.92 1.89 0.0009 <0.0001 1.97 3.91 <0.0001 <0.0001 No No 
217414_x_at 
hemoglobin, alpha 













GALNT5 0.97 1.95 <0.0001 <0.0001 0.34 1.27 0.0006 0.0011 No No 
203243_s_at 
PDZ and LIM 
domain 5 










PALLD 1.06 2.09 <0.0001 <0.0001 1 1.99 <0.0001 <0.0001 Yes No 
211681_s_at 
PDZ and LIM 
domain 5 
PDLIM5 1.09 2.14 <0.0001 <0.0001 1.15 2.22 <0.0001 <0.0001 No No 
221994_at 
PDZ and LIM 
domain 5 




SMAD7 1.22 2.34 <0.0001 <0.0001 0.91 1.88 <0.0001 <0.0001 No No 
215596_s_at 
listerin E3 ubiquitin 
protein ligase 1 
LTN1 1.23 2.35 <0.0001 <0.0001 2.24 4.74 <0.0001 <0.0001 No No 
203242_s_at 
PDZ and LIM 
domain 5 










PALLD 1.3 2.45 <0.0001 <0.0001 1.09 2.13 <0.0001 <0.0001 Yes No 
216804_s_at 
PDZ and LIM 
domain 5 
PDLIM5 1.33 2.52 <0.0001 <0.0001 1.1 2.15 <0.0001 <0.0001 No No 
214414_x_at 
hemoglobin, alpha 









PALLD 1.37 2.59 <0.0001 <0.0001 1.01 2.01 <0.0001 <0.0001 Yes No 
213684_s_at 
PDZ and LIM 
domain 5 
PDLIM5 1.56 2.95 <0.0001 <0.0001 1.38 2.6 <0.0001 <0.0001 No No 
215767_at 
zinc finger protein 
804A 




PDE4B 1.66 3.16 <0.0001 <0.0001 -2 0.25 <0.0001 <0.0001 No No 
200633_at ubiquitin B UBB 2.11 4.32 <0.0001 <0.0001 1.28 2.43 <0.0001 <0.0001 No No 
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204035_at secretogranin II SCG2 2.16 4.46 <0.0001 <0.0001 2.38 5.2 <0.0001 <0.0001 No No 
206172_at 
interleukin 13 
receptor, alpha 2 
IL13RA2 2.9 7.46 <0.0001 <0.0001 0.71 1.64 <0.0001 <0.0001 No No 
 
a
Results from triplicates for each sample (two separate experiments: parental versus MLL2-/- #1 
and #2; parental versus MLL2-/- #3 and #4). 
b
False discovery rate was calculated using 
Significance Analysis of Microarrays (SAM).  
c
Identified by ChIP (citation). 
d
Probes that 
displayed a down-regulation of 50% or more in the first experiment and were confirmed to be 
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